Emerging Dialysis Drugs Will Face Medicare Reimbursement Challenges
Executive Summary
Navigating Medicare's complicated bundled payment system could be tricky for new class of anemia drugs, the HIF prolyl hydroxylase inhibitors, which may start to reach the market for dialysis patients in 2019.
You may also be interested in...
Medicare Payment Policy For Dialysis Drugs Seeks To Promote Innovation, Restrain Costs
More new dialysis drugs would be eligible for Medicare add-on payments under proposed rule, but payment amounts would be lower.
Pfizer’s EPO Biosimilar Stalls In US On Hospira Compliance Woes
US FDA hands Pfizer its second complete response letter for its proposed biosimilar to Epogen/Procrit, citing manufacturing compliance concerns at a legacy Hospira manufacturing facility in Kansas that was the target of a February warning letter. Issue “is not directly related to EPO itself,” Pfizer’s Salomon Azoulay says.
Battle Lines Drawn In New Renal Anemia Market
The treatment landscape in renal anemia is set for major changes over the next few years as a novel class of drugs approaches the market. A new report from Biomedtracker looks at the major players battling it out in the clinic.